ALVO — Alvotech
Is ALVO overbought or oversold? Here is the current MarketMoodz read.
Alvotech (ALVO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $4.41. The rating moved from Neutral to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$4.41
- Last changeMoved from Neutral to Oversold on November 14, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Alvotech (ALVO) is positioned as a biosimilars specialist with manufacturing capabilities and partnership-led commercialization potential. Financial visibility is limited in the provided data, implying exposure to cash-burn and potential dilution risk; near-term value will hinge on regulatory milestones and initial commercial traction. Competitive pressure from incumbents and sector flows favoring large-cap pharma could constrain multiple expansion, while successful approvals and effective payer access would materially improve revenue prospects. Given the current information set, the stock appears to warrant cautious monitoring of filings, cash runway, and upcoming regulatory/commercial catalysts.
Key factors
- Pipeline focus on biosimilars with potential for steady long-term revenue if commercialization succeeds
- Vertical manufacturing capability that can lower COGS and support supply reliability versus some peers
- Partnerships and licensing deals provide non-dilutive revenue opportunities and commercialization reach
- Sector-wide investor preference for large-cap pharma may limit near-term inflows to mid-cap biosimilars
- No recent major filings available in the provided dataset, increasing uncertainty around near-term financial runway
- Regulatory approvals and successful market uptake are primary near-term value drivers
Risks
- Regulatory setbacks or slower-than-expected approvals for key biosimilar candidates
- Commercial competition from incumbent biologic manufacturers and other biosimilar entrants, pressuring pricing and share
- Balance-sheet constraints or need for additional financing that could dilute shareholders
- Manufacturing or quality-control disruptions that delay supply or approvals
- Limited liquidity and investor attention relative to large-cap pharma during defensive rotations
- Reimbursement and payer adoption challenges that reduce realized pricing and uptake
See today's live rating, score and targets
Members see the live hourly rating for ALVO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.